



Precision Diagnostics to Enhance  
Women's Health

David Holmes  
Provista Diagnostics  
IR@ProvistaDx.com  
212-202-3170

## **For Immediate Release**

### **Provista Diagnostics Announces Reelection of the Company's Board of Directors**

*Director Candidates Elected to Serve until the 2017 Annual Meeting*

**New York** – October 05, 2016 – Provista Diagnostics, Inc. is pleased to announce the election of the 2016 Board of Directors to serve for a one-year term. The members of the Company's Board of Directors are as follows: Anne Busquet, Jeffrey R. Gilman, Robert J. Hariri, PhD, Jack Levine CPA, John Macaskill, Thomas G. Mendell, David E. Reese, PhD, Yoji Nimura and John Zicarelli PhD, FCAS, CFA. The shareholders of Provista's preferred and common stock re-elected all of the nominees as Directors of the Company to serve until the 2017 Annual Meeting of Stockholders. The election took place at the 2016 Annual Meeting of Stockholders held last week at the company's headquarters in New York City.

## **About Provista**

Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based proteomic diagnostic, prognostic and monitoring tests designed to address the unmet needs in women's cancer, such as breast and gynecologic cancers. Provista Diagnostics' state-of-the-art, high-complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and with the Clinical Laboratory Improvement Amendments (CLIA).

Additional information about Provista Diagnostics is available at [ProvistaDx.com](http://ProvistaDx.com)

Information about Provista Diagnostics' clinical trials is available at [ClinicalTrials.gov](http://ClinicalTrials.gov)

## **Safe Harbor Statement**

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista's actual results may differ materially due to a number of factors, many of which are beyond Provista's ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

###